About Us

Treating, improving, and extending patients’ lives.

Our Vision

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients’ lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases.

Renibus’ first-in-a-new-class lead program is RBT-1, which is in a Phase 3 pivotal trial to show a reduction in post-operative complications and improve outcomes following cardiac surgery. The drug has received FDA Breakthrough and Fast Track Designations.

Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile, with a goal of identifying an indication for evaluation in a Phase 2 trial.

RBT-3 (iron sucrose), one component of RBT-1, is a novel, low molecular weight iron nanoparticle that has the potential to rapidly restore iron levels and improve blood product utilization in cardiac surgery and/or ER patients. RBT-3 has also demonstrated the potential to mitigate cisplatin induced nephrotoxicity in preclinical models. We are currently exploring opportunities to further the clinical development of RBT-3 in these potential indications.

RBT-9 (stannic protoporfin), another component of RBT-1, is a potent anti-inflammatory and antioxidant drug. It has completed Phase 1 (as part of the RBT-1 program) and has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated that RBT-9 has the potential to significantly improve clinical outcomes. Additional work is underway to help inform the future clinical development strategy.

RBT-2 (tetrahydrocurcumin) is an oral antioxidant and antifibrotic drug that may have the potential to delay CKD progression.

Our Leadership Team

D. Jeff Keyser, RPh, JD, PhD
President and CEO
Bhupinder Singh, MD
Chief Medical Officer
Jamie A. Donadio
Chief Financial Officer
Asha Ramdas
Chief Technical Officer

Board of Directors

Henrik Rasmussen, MD, PhD
D. Jeff Keyser, RPh, JD, PhD
President and CEO
Bhupinder Singh, MD
Carlos Guillem, MBA, PhD

Scientific Advisors

Alpesh Amin, MD, MBA, MACP, SFHM, FACC, FHFSA, FRCP (Lond)
Chair, Department of Medicine Professor of Medicine, Executive Director, Hospital Medicine. University of California, Irvine.
Rakesh Arora, BA, MD, PhD
Director – Perioperative and Cardiac Critical Care, Harrington Heart Vascular Institute, University Hospitals/Case Western Reserve University
Javed Butler, MD, MPH, MBA,
President of the Baylor Scott and White Research Institute. Senior Vice President for the Baylor Scott and White Health
Andre Lamy, MD, MSc
Cardiac Surgeon, Population Health Research Institute. McMaster University, Canada.
Kevin W. Lobdell, MD LTC, MC, USAR
Professor-System Director CV Surgical Quality, Education, & Research. Atrium Health – Sanger Heart & Vascular Institute.
Patrick T. Murray, MD, FASN, FRCPI, FJFICMI
Professor of Clinical Pharmacology at University College Dublin, Consultant Physician at the Mater Misericordiae. University Hospital, Dublin, Ireland.
Hamid Rabb, MD
Medical Director of the Johns Hopkins Kidney Transplant Program, Professor of Medicine. Johns Hopkins.
Andrew Shaw, MD, FRCA, FCCM, FFICM
Professor and Chair, Department of Intensive Care and Resuscitation, Cleveland Clinic.
Alexander Zarbock, MD, PhD
Professor of Anesthesiology and Intensive Care Medicine at the University of Münster and Chair of the Department of Anesthesiology, Intensive Care and Pain Medicine at the University Hospital Münster
Glenn M. Chertow, MD, MPH
Chief, Division of Nephrology, Stanford University School of Medicine
Norman S. Coplon Satellite Healthcare Professor in Medicine, Division of Nephrology, Stanford University School of Medicine

Laboratory of Basic
and Translational Research
Seattle, WA

Renibus’ translational lab, led by Dr. Richard Zager, keeps Renibus one step ahead of others in terms of innovating. This small, flexible and very efficient lab enables Renibus to get quick answers to important questions and explore new areas without the time and cost of outsourcing.

Richard A. Zager, MD
SVP Translational Research
Ali C.M. Johnson, MS
Staff Scientist